Xilio Therapeutics, Inc.
XLO
$8.46
-$0.05-0.59%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 43.77M | 31.80M | 15.00M | 9.27M | 6.34M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 43.77M | 31.80M | 15.00M | 9.27M | 6.34M |
| Cost of Revenue | -8.27M | -2.72M | -6.29M | -10.40M | -10.40M |
| Gross Profit | 52.03M | 34.53M | 21.29M | 19.67M | 16.74M |
| SG&A Expenses | 29.71M | 28.83M | 28.46M | 27.15M | 24.78M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 85.75M | 75.58M | 71.65M | 66.23M | 65.99M |
| Operating Income | -41.98M | -43.78M | -56.65M | -56.96M | -59.65M |
| Income Before Tax | -35.04M | -58.49M | -56.22M | -54.30M | -58.24M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -35.04 | -58.49 | -56.22 | -54.30 | -58.24 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -35.04M | -58.49M | -56.22M | -54.30M | -58.24M |
| EBIT | -41.98M | -43.78M | -56.65M | -56.96M | -59.65M |
| EBITDA | -40.44M | -42.18M | -55.02M | -55.26M | -58.00M |
| EPS Basic | -10.21 | -14.00 | -12.69 | -12.85 | -18.99 |
| Normalized Basic EPS | -6.38 | -8.75 | -7.94 | -8.03 | -11.57 |
| EPS Diluted | -10.21 | -14.00 | -12.69 | -12.85 | -18.99 |
| Normalized Diluted EPS | -6.38 | -8.75 | -7.94 | -8.03 | -11.57 |
| Average Basic Shares Outstanding | 23.58M | 17.36M | 18.19M | 17.63M | 14.29M |
| Average Diluted Shares Outstanding | 23.58M | 17.36M | 18.19M | 17.63M | 14.29M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |